帕比司他与芦可替尼治疗骨髓纤维化的Ib期剂量探索性研究。 - Suppr

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

作者信息

Harrison Claire, Heidel Florian H, Vannucchi Alessandro M, Kiladjian Jean-Jacques, Hayat Amjad, Passamonti Francesco, Conneally Eibhlin, Kindler Thomas, Martino Bruno, Lipka Daniel B, Stefanelli Tommaso, Roussou Pantelia, Germano Davide, Ewan Jacqueline, Ribrag Vincent

机构信息

Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom.

Internal Medicine C, University Medicine Greifswald, Germany.

出版信息

Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug.

DOI:10.1097/HS9.0000000000000757

PMID:35935608

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9348858/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c4e/9348858/23e018d0d5d9/hs9-6-e757-g001.jpg

相似文献

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.帕比司他与芦可替尼治疗骨髓纤维化的Ib期剂量探索性研究。

Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug.

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).一项评估泊马度胺和芦可替尼用于原发性骨髓纤维化（PMF）和真性红细胞增多症/原发性血小板增多症后骨髓纤维化（post--PV/ET MF）患者的 I 期研究。

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).帕比司他治疗原发性骨髓纤维化（PMF）和真性红细胞增多症/原发性血小板增多症后骨髓纤维化（post-PV/ET MF）患者的II期研究。

Leuk Res. 2017 Feb;53:13-19. doi: 10.1016/j.leukres.2016.11.015. Epub 2016 Nov 30.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.在既往接受过鲁索替尼治疗的骨髓纤维化患者中使用Janus激酶2抑制剂非格司亭（JAKARTA-2）：一项单臂、开放标签、非随机、2期、多中心研究。

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

Rationale for combination therapy in myelofibrosis.骨髓纤维化联合治疗的原理。

Best Pract Res Clin Haematol. 2014 Jun;27(2):197-208. doi: 10.1016/j.beha.2014.07.009. Epub 2014 Jul 18.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.COMFORT-II研究中鲁索替尼联合促红细胞生成素刺激剂用于骨髓纤维化患者：一项评估鲁索替尼与最佳可用疗法治疗骨髓纤维化疗效和安全性的开放标签3期研究。

Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.口服多聚去乙酰化酶抑制剂帕比司他治疗原发性骨髓纤维化、特发性血小板增多症后和真性红细胞增多症后骨髓纤维化的 II 期临床试验。

Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.Momelotinib对比最佳可用疗法治疗既往接受过鲁索替尼治疗的骨髓纤维化患者（SIMPLIFY 2）：一项随机、开放标签的3期试验

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.在 3b 期扩展准入 JUMP 研究中，分析骨髓纤维化患者对芦可替尼反应的预测因素。

Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19.

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.芦可替尼停药后的情况：218 例骨髓纤维化患者停药原因、疾病阶段的影响和结局。

Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.

引用本文的文献

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.髓系癌症中表观遗传靶分子与疗法的演变格局：聚焦急性髓系白血病和骨髓增殖性肿瘤

Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639-x.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征：对诊断、预后及治疗进展的意义

Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.

Recent advances in therapies for primary myelofibrosis.原发性骨髓纤维化治疗的最新进展

Fac Rev. 2023 Sep 26;12:23. doi: 10.12703/r/12-23. eCollection 2023.

Myelofibrosis.骨髓纤维化。

Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423.

本文引用的文献

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.组蛋白去乙酰化酶对趋化因子和细胞因子的调控及组蛋白去乙酰化酶抑制剂在人类疾病中的研究进展。

Int J Mol Sci. 2019 Mar 5;20(5):1110. doi: 10.3390/ijms20051110.

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.原发性骨髓纤维化中的驱动基因突变与预后：Mayo-Careggi MPN 联盟对 1095 例患者的研究。

Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.循环细胞因子水平作为费城阴性骨髓增殖性肿瘤炎症标志物的诊断和预后意义

Mediators Inflamm. 2015;2015:670580. doi: 10.1155/2015/670580. Epub 2015 Oct 7.

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.JAK1/2 和 Pan-去乙酰化酶抑制剂联合治疗在 JAK2V617F 驱动疾病的临床前小鼠模型中提高了疗效。

Clin Cancer Res. 2013 Nov 15;19(22):6230-41. doi: 10.1158/1078-0432.CCR-13-0905. Epub 2013 Sep 30.

Treatment and management of myelofibrosis in the era of JAK inhibitors.JAK抑制剂时代骨髓纤维化的治疗与管理

Biologics. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20.

Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.

Mutations and prognosis in primary myelofibrosis.原发性骨髓纤维化中的突变与预后。

Leukemia. 2013 Sep;27(9):1861-9. doi: 10.1038/leu.2013.119. Epub 2013 Apr 26.

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.一项在晚期血液系统恶性肿瘤患者中进行的口服帕比司他两种给药方案的 Ia/II 期、两臂、开放性、剂量递增研究。

Leukemia. 2013 Aug;27(8):1628-36. doi: 10.1038/leu.2013.38. Epub 2013 Feb 6.

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).一项评估 panobinostat（LBH589）在原发性骨髓纤维化（PMF）和真性红细胞增多症/原发性血小板增多症后骨髓纤维化（post-PV/ET MF）患者中的 I 期研究。

Br J Haematol. 2013 Apr;161(1):68-75. doi: 10.1111/bjh.12220. Epub 2013 Jan 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献